Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTMX NASDAQ:EDIT NASDAQ:PRAX NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$4.02+0.4%$4.66$0.91▼$8.21$679.90M2.185.74 million shs1.74 million shsEDITEditas Medicine$3.15+3.8%$2.68$1.35▼$4.54$306.94M2.141.67 million shs343,330 shsPRAXPraxis Precision Medicines$337.09+1.1%$317.78$35.21▼$356.00$9.41B2.76457,310 shs84,141 shsSRPTSarepta Therapeutics$20.03-3.7%$19.77$10.41▼$44.14$2.11B0.262.88 million shs761,845 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics-3.15%-5.21%-6.98%-29.45%+311.10%EDITEditas Medicine-4.42%+1.00%+10.58%+66.48%+127.82%PRAXPraxis Precision Medicines-1.42%+4.53%+8.67%+4.29%+774.98%SRPTSarepta Therapeutics-9.68%-0.38%-9.88%+12.43%-43.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$4.02+0.4%$4.66$0.91▼$8.21$679.90M2.185.74 million shs1.74 million shsEDITEditas Medicine$3.15+3.8%$2.68$1.35▼$4.54$306.94M2.141.67 million shs343,330 shsPRAXPraxis Precision Medicines$337.09+1.1%$317.78$35.21▼$356.00$9.41B2.76457,310 shs84,141 shsSRPTSarepta Therapeutics$20.03-3.7%$19.77$10.41▼$44.14$2.11B0.262.88 million shs761,845 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics-3.15%-5.21%-6.98%-29.45%+311.10%EDITEditas Medicine-4.42%+1.00%+10.58%+66.48%+127.82%PRAXPraxis Precision Medicines-1.42%+4.53%+8.67%+4.29%+774.98%SRPTSarepta Therapeutics-9.68%-0.38%-9.88%+12.43%-43.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTMXCytomX Therapeutics 2.80Moderate Buy$13.44234.86% UpsideEDITEditas Medicine 2.57Moderate Buy$5.4071.70% UpsidePRAXPraxis Precision Medicines 3.00Buy$592.7875.85% UpsideSRPTSarepta Therapeutics 2.11Hold$27.7138.37% UpsideCurrent Analyst Ratings BreakdownLatest SRPT, CTMX, EDIT, and PRAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026PRAXPraxis Precision Medicines Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$420.005/8/2026PRAXPraxis Precision Medicines WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderperform$130.00 ➝ $166.005/8/2026PRAXPraxis Precision Medicines BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$843.005/7/2026PRAXPraxis Precision Medicines Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/5/2026EDITEditas Medicine Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.50 ➝ $4.004/22/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)4/20/2026EDITEditas Medicine Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/16/2026SRPTSarepta Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell4/15/2026PRAXPraxis Precision Medicines Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$437.004/14/2026PRAXPraxis Precision Medicines Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$510.004/10/2026PRAXPraxis Precision Medicines Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$815.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTMXCytomX Therapeutics$76.20M8.97N/AN/A$0.58 per share6.92EDITEditas Medicine$38.69M7.96N/AN/A$0.05 per share62.90PRAXPraxis Precision Medicines$8.55M1,098.80N/AN/A$34.85 per share9.67SRPTSarepta Therapeutics$2.20B0.96N/AN/A$10.89 per share1.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTMXCytomX Therapeutics-$17.37M-$0.04N/AN/AN/A-22.79%-19.77%-11.91%N/AEDITEditas Medicine-$160.06M-$1.23N/AN/AN/A-281.59%-677.39%-58.25%5/11/2026 (Estimated)PRAXPraxis Precision Medicines-$303.27M-$13.46N/AN/AN/AN/A-58.74%-53.54%N/ASRPTSarepta Therapeutics-$713.41M-$8.44N/A9.910.35-2.94%7.90%2.87%N/ALatest SRPT, CTMX, EDIT, and PRAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026EDITEditas Medicine-$0.30-$0.26+$0.04-$0.26$6.37 million$2.83 million5/7/2026Q1 2026CTMXCytomX Therapeutics-$0.14-$0.10+$0.04-$0.10$4.68 million$10.26 million5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A5/6/2026Q1 2026SRPTSarepta Therapeutics$0.9760$3.16+$2.1840$2.88$474.16 million$730.80 million3/16/2026Q4 2025CTMXCytomX Therapeutics-$0.08-$0.22-$0.14-$0.22$7.33 million$0.66 million3/9/2026Q4 2025EDITEditas Medicine-$0.27-$0.06+$0.21-$0.06$8.77 million$24.74 million2/25/2026Q4 2025SRPTSarepta Therapeutics-$0.87-$3.58-$2.71-$3.93$390.95 million$442.93 million2/19/2026Q4 2025PRAXPraxis Precision Medicines-$3.00-$3.50-$0.50-$3.50$0.26 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTMXCytomX TherapeuticsN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTMXCytomX TherapeuticsN/A3.093.09EDITEditas MedicineN/A3.223.54PRAXPraxis Precision MedicinesN/A10.2210.22SRPTSarepta Therapeutics0.732.321.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTMXCytomX Therapeutics67.77%EDITEditas Medicine71.90%PRAXPraxis Precision Medicines67.84%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipCTMXCytomX Therapeutics6.60%EDITEditas Medicine2.10%PRAXPraxis Precision Medicines2.70%SRPTSarepta Therapeutics6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTMXCytomX Therapeutics170170.19 million158.96 millionOptionableEDITEditas Medicine23097.91 million95.85 millionOptionablePRAXPraxis Precision Medicines11027.87 million27.12 millionOptionableSRPTSarepta Therapeutics1,372105.57 million98.29 millionOptionableSRPT, CTMX, EDIT, and PRAX HeadlinesRecent News About These CompaniesSarepta (SRPT) Q1 2026 Earnings TranscriptMay 8 at 3:04 AM | finance.yahoo.comSRPT stock plunges 7% after-hours as Elevidys demand slumps — CEO still sees return to growthMay 8 at 3:04 AM | msn.comSarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 11.8% - Should You Sell?May 7 at 6:12 PM | marketbeat.comSarepta Therapeutics, Inc. Q1 2026 Earnings Call SummaryMay 7 at 12:02 PM | app.moby.coASarepta Stock Slumps. Why an Earnings Beat Wasn’t Enough for the S&P 500 Loser.May 7 at 12:02 PM | finance.yahoo.comSarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?May 7 at 12:02 PM | finance.yahoo.comSarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook MaintainedMay 7 at 11:51 AM | zacks.comSarepta Therapeutics: Hold Rating Reaffirmed as Strong Elevidys Sales Offset by Pipeline and Execution UncertaintiesMay 7 at 8:50 AM | tipranks.comSarepta Therapeutics: Safety Overhangs and Regulatory Uncertainty Reinforce Sell Rating and Unchanged $13 Price TargetMay 7 at 6:51 AM | tipranks.comSarepta Therapeutics Q1 Earnings Call HighlightsMay 7 at 2:06 AM | marketbeat.comSarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call TranscriptMay 6 at 12:01 AM | seekingalpha.comSarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate DevelopmentsMay 6 at 8:59 PM | finance.yahoo.comSarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top EstimatesMay 6 at 8:59 PM | finance.yahoo.comSarepta Therapeutics (SRPT) Reports Q1 Earnings: What Key Metrics Have to SayMay 6 at 8:59 PM | finance.yahoo.comSarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check.May 6 at 8:59 PM | finance.yahoo.comSarepta Therapeutics (SRPT) Reports Q1 Earnings: What Key Metrics Have to SayMay 6 at 7:31 PM | zacks.comSarepta Therapeutics, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 6 at 6:31 PM | seekingalpha.comSarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top EstimatesMay 6 at 6:25 PM | zacks.comSarepta Therapeutics (NASDAQ:SRPT) Releases Quarterly Earnings ResultsMay 6 at 4:26 PM | marketbeat.comSarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate DevelopmentsMay 6 at 4:05 PM | businesswire.comSarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings GrowthApril 29, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThis AI Lender Has Big Upside Potential—And Big Risks By Peter Frank | April 19, 20263 Biotech Stocks That Could Benefit from the Patent CliffBy Chris Markoch | April 27, 2026NerdWallet’s Growth Story Looks Strong—But Can It Last?By Peter Frank | April 30, 2026Capital One’s Big Bet Faces Rising Credit RiskBy Peter Frank | May 6, 2026CPI Card Group’s Quiet Cash Machine Faces a Digital Reality CheckBy Peter Frank | May 4, 2026SRPT, CTMX, EDIT, and PRAX Company DescriptionsCytomX Therapeutics NASDAQ:CTMX$4.01 +0.02 (+0.38%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Editas Medicine NASDAQ:EDIT$3.14 +0.12 (+3.80%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Praxis Precision Medicines NASDAQ:PRAX$337.09 +3.81 (+1.14%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Sarepta Therapeutics NASDAQ:SRPT$20.02 -0.78 (-3.73%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
